Using Circulating Tumor DNA to Monitor Immunotherapy in Lung Cancer
Author Information
Author(s): Hebert Brandon, Bradley James, Normanno Nicola
Primary Institution: University of Louisville School of Medicine
Hypothesis
Can circulating tumor DNA (ctDNA) be used as a biomarker to predict immunotherapy response in non-small cell lung cancer (NSCLC)?
Conclusion
Circulating tumor DNA levels can provide valuable insights into treatment response and prognosis for patients with non-small cell lung cancer undergoing immunotherapy.
Supporting Evidence
- Reduction in ctDNA levels is associated with improved overall survival and progression-free survival.
- ctDNA can detect immunotherapy response after about 8 weeks.
- ctDNA allows for serial monitoring to detect developing resistance and genomic variants.
- ctDNA provides a non-invasive method for comprehensive molecular profiling.
Takeaway
Doctors can use a blood test to check for tiny bits of cancer DNA to see if lung cancer treatment is working.
Methodology
The study reviews existing literature and clinical trials on the use of ctDNA in monitoring immunotherapy response in NSCLC.
Potential Biases
There is a risk of bias due to the variability in ctDNA assays and the influence of external factors on ctDNA levels.
Limitations
Factors like patient comorbidities and variability in ctDNA detection methods can affect the accuracy of ctDNA analysis.
Participant Demographics
The study involves patients with non-small cell lung cancer, including those with early and late-stage disease.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI, 1.62 to 3.20
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website